Top 10 Highlights from ASCO 2015

References:

1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). Presented at the 2015 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago. Abstract LBA1.

2. Brown PD, Asher AL, Ballman KV, et al. NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. Presented at the 2015 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago. Abstract LBA4.

3. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch repair deficiency. Presented at the 2015 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago. Abstract LBA100.

4. Sandler HM, Hu C, Rosenthal SA, et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). Presented at the 2015 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago. Abstract LBA5002.

5. Turner NC, Ro J, Andre F, et al. PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. Presented at the 2015 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago. Abstract LBA502.

6. Schöffski P, Maki RG, Italiano A, et al. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). Presented at the 2015 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago. Abstract LBA10502.

7. Chanan-Khan AAA, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study. Presented at the 2015 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago. Abstract LBA7005.

8. D’Cruz A, Dandekar M, Vaish R, et al. Elective versus therapeutic neck dissection in the clinically node negative early oral cancer: A randomised control trial (RCT). Presented at the 2015 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago. Abstract LBA3.

9. Armstrong GT, Yasui Y, Chen Y, et al. Reduction in late mortality among 5-year survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). Presented at the 2015 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago. Abstract LBA2.

10. Margolese RG, Cecchini RS, Julian TB, et al. Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. Presented at the 2015 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago. Abstract LBA500.